Vanda Pharmaceuticals Inc.
VNDA
$5.02
$0.0951.93%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 198.77M | 190.86M | 182.02M | 177.60M | 192.64M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 198.77M | 190.86M | 182.02M | 177.60M | 192.64M |
| Cost of Revenue | 11.31M | 12.18M | 12.70M | 13.46M | 14.80M |
| Gross Profit | 187.46M | 178.67M | 169.33M | 164.14M | 177.84M |
| SG&A Expenses | 146.41M | 130.75M | 117.94M | 106.86M | 112.88M |
| Depreciation & Amortization | 7.27M | 6.47M | 5.10M | 3.73M | 2.09M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 239.43M | 228.33M | 214.49M | 202.80M | 206.59M |
| Operating Income | -40.66M | -37.48M | -32.47M | -25.19M | -13.95M |
| Income Before Tax | -22.92M | -18.09M | -11.96M | -3.85M | 6.34M |
| Income Tax Expenses | -4.02M | -1.70M | -1.03M | 1.04M | 3.83M |
| Earnings from Continuing Operations | -18.90 | -16.39 | -10.93 | -4.89 | 2.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.90M | -16.39M | -10.93M | -4.89M | 2.51M |
| EBIT | -40.66M | -37.48M | -32.47M | -25.19M | -13.95M |
| EBITDA | -32.53M | -30.16M | -26.54M | -20.63M | -10.94M |
| EPS Basic | -0.33 | -0.28 | -0.19 | -0.08 | 0.04 |
| Normalized Basic EPS | -0.32 | -0.29 | -0.22 | -0.14 | -0.03 |
| EPS Diluted | -0.33 | -0.29 | -0.20 | -0.09 | 0.04 |
| Normalized Diluted EPS | -0.32 | -0.29 | -0.22 | -0.14 | -0.03 |
| Average Basic Shares Outstanding | 232.55M | 231.78M | 231.03M | 230.27M | 229.52M |
| Average Diluted Shares Outstanding | 232.55M | 231.78M | 231.11M | 230.42M | 230.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
